ALX Oncology
ALXO
108 hedge funds and large institutions have $144M invested in ALX Oncology in 2026 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 32 reducing their positions, and 4 closing their positions.
13,700% more call options, than puts
Call options by funds: $138K | Put options by funds: $1K
425% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 4
16% more funds holding
Funds holding: 93 → 108 (+15)
13% more capital inflows, than outflows
Capital inflows: $21.5M | Capital outflows: $19M
0% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 32
3.12% less ownership
Funds ownership: 78.17% → 75.05% (-3.1%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squadron Capital Management
Westmont,
Illinois
|
+$2.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.57M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.35M |
| 4 |
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.59M |
| 5 |
Millennium Management
New York
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vivo Capital
Palo Alto,
California
|
-$6.59M |
| 2 |
TCG Crossover Management
Palo Alto,
California
|
-$6.16M |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.55M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$733K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$595K |
ALXO Hedge Fund Activity: Q3 2026 in Review
108 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2026, worth a combined $144M — down 34% from $218M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ALXO positions and 4 closed out — a net gain of 17 holders — while 32 added to existing stakes and 32 trimmed.
The largest buyer was Squadron Capital Management, opening a new position worth an estimated $2.7M. The largest seller was Vivo Capital, exiting entirely with an estimated $6.59M sold.
- 108 institutional investors held ALX Oncology (ALXO) as of Q3 2026, up from 93 in Q2 2026.
- Funds reported $144M of ALX Oncology stock for Q3 2026, down 34% quarter-over-quarter.
- 21 funds opened new ALX Oncology positions in Q3 2026 and 4 closed out, a net change of +17 holders.
- The largest ALX Oncology buyer in Q3 2026 was Squadron Capital Management, an estimated $2.7M added.
- The largest ALX Oncology seller in Q3 2026 was Vivo Capital, an estimated $6.59M sold.
Based on aggregated 13F filings for Q3 2026.